Blood Screening Market to Grow with a CAGR of 5.25% through 2029

Rising Incidence of Infectious Diseases and Rising Healthcare Expenditure are factors driving the Global Blood Screening Market in the forecast period 2025-2029.

According to TechSci Research report, “Blood Screening Market – Global Industry Size, Share, Trends, Competition Forecast & Opportunities, 2029F”, the Global Blood Screening Market stood at USD 2.52 Billion in 2023 and is anticipated to grow with a CAGR of 5.25% in the forecast period through 2029. The prevalence of infectious diseases such as HIV, hepatitis, and other blood-borne infections continues to be a major concern globally. The demand for blood screening solutions has surged in response to the need for early detection and prevention of these diseases. Governments and healthcare organizations are increasingly investing in advanced blood screening technologies to ensure the safety of blood transfusions and reduce the risk of disease transmission. Technological innovations have played a pivotal role in transforming blood screening processes. The development of high-throughput screening techniques, nucleic acid testing, and automation has enhanced the efficiency and accuracy of blood screening. These advancements not only ensure faster results but also contribute to the overall improvement of blood safety standards. The integration of cutting-edge technologies continues to be a driving force in the market's expansion.

The global awareness campaigns and initiatives promoting voluntary blood donation have led to an increase in blood donation rates. As the volume of donated blood rises, the need for effective blood screening solutions becomes more pronounced. Blood screening helps identify potential health risks in donated blood, ensuring the safety of both donors and recipients. The growing culture of voluntary blood donation is a significant factor propelling the demand for blood screening services.

Governments and regulatory bodies across the globe are imposing increasingly stringent standards for blood safety. Compliance with these regulations is crucial for blood banks, hospitals, and diagnostic laboratories. The necessity to adhere to strict quality and safety standards has driven the adoption of advanced blood screening technologies. Companies in the blood screening market are continuously striving to meet and exceed these standards, fostering market growth. The overall increase in healthcare expenditure globally has positively impacted the blood screening market. Governments and private healthcare institutions are allocating more resources to enhance healthcare infrastructure, including blood screening facilities. The willingness to invest in advanced technologies and equipment has contributed to the expansion of the blood screening market.

Browse over XX market data Figures spread through XX Pages and an in-depth TOC on "Global Blood Screening Market”

The Global Blood Screening Market is segmented into technology, product, region and company.

Based on technology, The Nucleic Acid Amplification Test (NAT) segment is projected to experience rapid growth during the forecast period. Nucleic Acid Amplification Test (NAT) is a molecular biology technique designed to detect the presence of nucleic acids, such as DNA or RNA, in a given sample. In the context of blood screening, NAT is employed to identify viral and bacterial infections that might be present in blood donations. This advanced testing method offers several advantages over traditional screening techniques, including higher sensitivity, faster results, and the ability to detect low levels of infectious agents. NAT has proven to be more sensitive and specific compared to traditional serological tests. This heightened sensitivity allows for the detection of infections in the early stages, reducing the risk of transmission through blood transfusions. The specificity of NAT ensures accurate identification of the target pathogen, minimizing the likelihood of false positives or negatives. One of the key advantages of NAT is its ability to significantly reduce the window period – the time between infection and detectability. Traditional screening methods might miss infections during this period, whereas NAT can detect viral or bacterial genetic material even before the onset of symptoms, enhancing the safety of the blood supply.

Based on region, The Asia Pacific region is experiencing rapid market growth. The prevalence of infectious diseases has been a driving factor for the growth of the blood screening market in Asia Pacific. The region has faced various public health challenges, including outbreaks of diseases such as HIV, hepatitis, and emerging infectious threats. In response, there has been an increased focus on implementing comprehensive blood screening protocols to prevent the transmission of these diseases, leading to a surge in demand for advanced screening technologies.

Major companies operating in Global Blood Screening Market are:

•        Abbott Laboratories Inc.
•        Danaher Corporation (Beckman Coulter)
•        Becton Dickinson and Company
•        Bio-Rad Laboratories, Inc.
•        Hoffman-La Roche Ltd.
•        Grifols, S.A.
•        Ortho-Clinical Diagnostics, Inc.
•        Siemens Healthineers AG
•        Thermo Fisher Scientific, Inc.
• SOFINA s.a (Biomerieux)

Download Free Sample Report

Customers can also request 10% free customization in this report

"The Global Blood Screening Market is experiencing robust growth, fueled by a combination of factors ranging from technological advancements to increasing awareness about blood safety. As the healthcare industry continues to evolve, the importance of efficient and accurate blood screening processes cannot be overstated. The market's trajectory is likely to remain upward as innovation persists and stakeholders prioritize the safety of blood transfusions and healthcare practices on a global scale.” said Mr. Karan Chechi, Research Director of TechSci Research, a research-based management consulting firm.

“Blood Screening Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Technology (Nucleic Acid Amplification Test (NAT), ELISA, Chemiluminescence Immunoassay (CLIA) and Enzyme Immunoassay (EIA), Next Generation Sequencing (NGS), Western Blotting), By Product (Reagent, Instrument), By Region and Competition, 2019-2029F”, has evaluated the future growth potential of Global Blood Screening Market and provides statistics & information on market size, structure and future market growth. The report intends to provide cutting-edge market intelligence and help decision makers take sound investment decisions. Besides, the report also identifies and analyzes the emerging trends along with essential drivers, challenges, and opportunities in Global Blood Screening Market.

Contact

TechSci Research LLC

420 Lexington Avenue, Suite 300,

New York, United States- 10170

Tel: +1-332-258-6602

Email: [email protected]

Website: www.techsciresearch.com